Merck's Keytruda fails Phase III in second-line gastric cancer

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab (MK-3475) as second-line treatment missed the primary endpoints in the Phase III KEYNOTE-061 trial in previously treated patients with advanced gastric or gastroesophageal junction

Read the full 328 word article

User Sign In